The emergence of compounds like copyright and Semaglutide signifies a major shift in how we approach blood sugar. These innovative therapies belong to a class known as GLP-1 action agonists, which duplicate the effects of a natural hormone that controls glucose levels and hunger. First, developed for managing blood sugar, their effectiveness in pro